Company: GANX
Filing Date: 2025-08-12
Form Type: 8-K
Source: 0001558370-25-011218
Chunk: 0

Company: Gain Therapeutics, Inc.
Filing Date: 2025-08-12
Form: 8-K
Item: Item 2.02
Chunk 0
---
Item 2.02 Results of Operations and Financial Condition.

On August 12, 2025, Gain Therapeutics, Inc. (the “ Company”) issued a press release announcing its financial results for the second quarter ended June 30, 2025, and a business update. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information included or incorporated in this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act”), or otherwise subject to the liabilities of that section, nor shall such information and exhibit be deemed incorporated by reference into any of the Company’s filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

The exhibits listed below are furnished as part of this Current Report on Form 8-K.

  Exhibit No.      Description                                                                   
         99.1      Gain Therapeutics, Inc. Press Release dated August 12, 2025                   
 ─────────────────────────────────────────────────────────────────────────────────────────────────
          104      Cover Page Interactive Data File (embedded within the Inline XBRL document).  

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

                             GAIN THERAPEUTICS, INC.                                                  
  Date: August 12, 2025      By:                          /s/ Gene Mack                               
                             Name:                                           Gene Mack                
                             Title:                                          Chief Executive Officer